NCT03570918View on ClinicalTrials.gov

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

September 28, 2021

Study Completion Date

September 28, 2021

Conditions
HIV-1-infection
Interventions
BIOLOGICAL

MGD014

HIV-1 x CD3 bispecific DART molecule

Trial Locations (1)

27599

University of North Carolina Chapel Hill, Chapel Hill

Sponsors

Lead Sponsor

MacroGenics
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

MacroGenics

INDUSTRY